https://scholars.lib.ntu.edu.tw/handle/123456789/487249
標題: | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | 作者: | JIH-HSIANG LEE WEI-WU CHEN CHIH-HUNG HSU Yen Y.-H. CHIH-HSIN YANG ANN-LII CHENG Sasaki S.-I. Chiu L.Y. Sugihara M. Ishizuka T. Oguma T. Tajima N. CHIA-CHI LIN |
公開日期: | 2020 | 出版社: | Springer | 卷: | 38 | 期: | 1 | 起(迄)頁: | 99-110 | 來源出版物: | Investigational New Drugs | 摘要: | Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I, nonrandomized, open-label multiple-dose study evaluated pexidartinib safety and efficacy in Asian patients with symptomatic, advanced solid tumors. Materials and Methods Patients received pexidartinib: cohort 1, 600?mg/d; cohort 2, 1000?mg/d for 2?weeks, then 800?mg/d. Primary objectives assessed pexidartinib safety and tolerability, and determined the recommended phase 2 dose; secondary objectives evaluated efficacy and pharmacokinetic profile. Results All 11 patients (6 males, 5 females; median age 64, range 23–82; cohort 1 n = 3; cohort 2 n = 8) experienced at least one treatment-emergent adverse event; 5 experienced at least one grade ? 3 adverse event, most commonly (18%) for each of the following: increased aspartate aminotransferase, blood alkaline phosphatase, gamma-glutamyl transferase, and anemia. Recommended phase 2 dose was 1000?mg/d for 2?weeks and 800?mg/d thereafter. Pexidartinib exposure, area under the plasma concentration-time curve from zero to 8?h (AUC0-8h), and maximum observed plasma concentration (Cmax) increased on days 1 and 15 with increasing pexidartinib doses, and time at Cmax (Tmax) was consistent throughout all doses. Pexidartinib exposure and plasma levels of adiponectin and colony-stimulating factor 1 increased following multiple daily pexidartinib administrations. One patient (13%) with tenosynovial giant cell tumor showed objective tumor response. Conclusions This was the first study to evaluate pexidartinib in Asian patients with advanced solid tumors. Pexidartinib was safe and tolerable in this population at the recommended phase 2 dose previously determined for Western patients (funded by Daiichi Sankyo; clinicaltrials.gov number, NCT02734433). ? 2019, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062708549&doi=10.1007%2fs10637-019-00745-z&partnerID=40&md5=ac9be5f41e6978f5292b125c55a1a7cb https://scholars.lib.ntu.edu.tw/handle/123456789/487249 |
ISSN: | 0167-6997 | DOI: | 10.1007/s10637-019-00745-z | SDG/關鍵字: | adiponectin; alkaline phosphatase; aspartate aminotransferase; bilirubin; colony stimulating factor 1; gamma glutamyltransferase; pexidartinib; aminopyridine derivative; CSF1R protein, human; granulocyte macrophage colony stimulating factor receptor; pexidartinib; pyrrole derivative; tumor marker; adult; aged; anemia; area under the curve; Article; Asian; backache; cancer patient; clinical article; cohort analysis; diarrhea; disease exacerbation; drug blood level; drug dose escalation; drug efficacy; drug safety; drug tolerability; fatigue; female; hair color; human; hypertransaminasemia; male; maximum concentration; open study; pharmacodynamics; phase 1 clinical trial; priority journal; solid malignant neoplasm; clinical trial; controlled clinical trial (topic); follow up; maximum tolerated dose; metabolism; middle aged; neoplasm; pathology; prognosis; tissue distribution; very elderly; young adult; Adult; Aged; Aged, 80 and over; Aminopyridines; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Non-Randomized Controlled Trials as Topic; Prognosis; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tissue Distribution; Young Adult |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。